Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Dividend Yield Fund median (12 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Feb 2026 – 20 Aug 2026, limited by Kotak Dividend Yield Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Kotak Dividend Yield Fund | Nifty 500 |
|---|---|---|
| 03 Feb 2026 | ₹100.00 | ₹100.00 |
| 20 Feb 2026 | ₹99.96 | ₹99.78 |
| 08 Mar 2026 | ₹97.10 | ₹95.88 |
| 25 Mar 2026 | ₹92.12 | ₹91.61 |
| 10 Apr 2026 | ₹95.28 | ₹95.31 |
| 27 Apr 2026 | ₹96.09 | ₹97.33 |
| 13 May 2026 | ₹94.00 | ₹95.44 |
| 30 May 2026 | ₹94.47 | ₹96.63 |
| 15 Jun 2026 | ₹95.70 | ₹97.63 |
| 02 Jul 2026 | ₹97.49 | ₹99.23 |
| 18 Jul 2026 | ₹97.82 | ₹99.53 |
| 04 Aug 2026 | ₹99.58 | ₹101.04 |
| 20 Aug 2026 | ₹98.54 | ₹100.28 |
| Metric | Kotak Mahindra · Direct · IDCW NAV ₹9.88 Very High risk Unrated | Category median Dividend Yield Fund · 12 funds |
|---|---|---|
| — | -0.52% | |
| — | +10.62% | |
| — | +9.95% | |
| — | +7.72% | |
| -1.46% | +8.77% | |
| +8.35% | — | |
| — | +12.23% | |
| — | +9.99% | |
| — | +8.64% | |
| Risk | ||
| 15.20% | 15.14% | |
| — | 0.13 | |
| — | 0.16 | |
| -12.28% | -22.06% | |
| Nifty 500 | — | |
| — | -0.78% | |
| — | 0.94 | |
| — | 90.9% | |
| — | 95.2% | |
| 1.10% | 1.07% | |
| ₹227.51Cr | ₹1,253Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 1% | 8% | |
| Abhishek Bisen | — | |
| 03 Feb 2026 | — | |
| 49 | — | |
| 35.7% | — | |
| 3.1% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.